Decentralized longevity trials hinge on data architecture
The Data Infrastructure Problem
Designerly's Cooper Adwin explains how regulatory governance and secure data infrastructure determine the success of distributed clinical studies in the longevity biotech sector.
The company is building the digital backbone for decentralized clinical trials. Adwin argues that without robust data architecture, trials cannot validate endpoints across multiple sites and jurisdictions.
Decentralized trials collect data from many locations. This creates a complex web of data flows. Adwin notes that tracking biomarker endpoints requires secure exchange and sustained access to historical records.
Why Governance Matters More Than Technology
Regulatory bodies demand strict governance over this data. If the architecture fails, the trial fails. Adwin stresses that data infrastructure sits on the critical path to clinical validation.
Technology alone does not guarantee trial success. Regulatory governance defines what data can be shared, stored, and accessed. Without clear rules, data silos form.
Adwin warns that fragmented data prevents meaningful analysis. The solution combines secure exchange protocols with long-term archival access. This ensures biomarker data remains usable across the trial's full duration.
Frequently Asked Questions
What makes decentralized longevity trials different from traditional ones? Decentralized trials collect data from multiple sites and jurisdictions simultaneously. This requires a unified data architecture to track endpoints consistently.
Why is historical data access critical? Longevity studies span years or decades. Researchers must access historical records to track biomarker changes over time.
What role does regulatory governance play? Governance sets the rules for data sharing and storage. It ensures compliance across different regulatory environments while maintaining data integrity.